Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Lee, Stephanie J., Kukreja, Manisha, Wang, Tao, Giralt, Sergio A., Szer, Jeffrey, Arora, Mukta, Woolfrey, Ann E., Cervantes, Francisco, Champlin, Richard E., Gale, Robert Peter, Halter, Joerg, Keating, Armand, Marks, David I., McCarthy, Philip L., Olavarria, Eduardo, Stadtmauer, Edward A., Abecasis, Manuel, Gupta, Vikas, Khoury, H. Jean, George, Biju, Hale, Gregory A., Liesveld, Jane L., Rizzieri, David A., Antin, Joseph H., Bolwell, Brian J., Carabasi, Matthew H., Copelan, Edward, Ilhan, Osman, Litzow, Mark R., Schouten, Harold C., Zander, Axel R., Horowitz, Mary M., Maziarz, Richard T.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2008
Schlagworte:
Transplantation
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2954751/
https://ncbi.nlm.nih.gov/pubmed/18664621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-02-141689
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge